Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
AffiliationThe Prostate Centre, London, UK.
MetadataShow full item record
AbstractHormonal therapy is the main recommended treatment for locally advanced and metastatic prostate cancer. Luteinizing hormone-releasing hormone (LHRH) agonists, such as buserelin, goserelin, leuprorelin and triptorelin, stimulate the pituitary's gonadotrophin-releasing hormone (GnRH) receptor, ultimately leading to its de-sensitization and subsequent reduction of LH and testosterone levels. However, this reduction is accompanied by a well described increase or 'surge' in LH and testosterone levels, necessitating the concomitant administration of an antiandrogen to combat the potential effects of transient acceleration in cancer activity. Two pure GnRH antagonists have been developed, abarelix and degarelix, that are devoid of any agonist effect on the GnRH receptor and consequently do not result in testosterone flare. Abarelix was the first GnRH antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone-dependent prostate carcinoma, when rapid androgen suppression is necessary. Clinical data on both abarelix and degarelix show that they can produce rapid and sustained decreases in testosterone to castrate levels without the need for co-administration of an antiandrogen, and with a very low complication rate in the short term.
CitationAbarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. 2009, 104 (11):1580-4 BJU Int.
- New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
- Authors: Garnick MB, Mottet N
- Issue date: 2012 Aug
- The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
- Authors: Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB
- Issue date: 2001 May
- Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
- Authors: Van Poppel H, Klotz L
- Issue date: 2012 Jul
- Degarelix: a new approach for the treatment of prostate cancer.
- Authors: Persson BE, Kold Olesen T, Jensen JK
- Issue date: 2009
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
- Authors: Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH
- Issue date: 2008 Dec